CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC Meeting Abstract

  

Authors:	Seidman, A. D.; Berry, D.; Cirrincione, C.; Harris, L.; Dressler, L.; Muss, H.; Norton, L.; Winer, E.; Hudis, C.
Abstract Title:	CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
Meeting Title:	40th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	22
Issue:	14 Suppl.
Meeting Dates:	2004 Jun 5-8
Meeting Location:	New Orleans, LA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2004-07-15
Start Page:	6S
Language:	English
ACCESSION:	WOS:000223512400020
PROVIDER:	wos
DOI:	10.1200/jco.2004.22.90140.512
Notes:	Meeting Abstract: 512 -- 40th Annual Meeting of the American-Society-of-Clinical-Oncology -- JUN 05-08, 2004 -- New Orleans, LA -- S -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/57699